Edwin Posadas, MD is the listed sponsor of NCT01834651 - currently #1 or 43 at clinicaltrialsdotgov.
Dr Posadas has a notable history as a researcher/publisher on FYN ...an oncogene known to overexpress in mCRPC...and also known to play an important role in PC metastasis downstream of the HGF/ MET signalling pathway. His work displays some interesting analysis of the working relationships between FYN, HGF/MET signalling, and CD-44. No small wonder this former NCI-investigator has taken an interest in Cabozantinib. It appears to play right into his ballpark. Lots of publications...
He is currently the medical director Cedar Sinai's UOP - West Hollywood, CA.
I grabbed the following quote from a 4/1/13 Cedar-Sinai press release. These docs at Sam Oschin Comprehensive Cancer Institute are also working on what appears to be a very advanced 3-way CTC capture platform. Dr Lu (quoted below) is a team-member of Posada's prostate research endeavor at CSSOCCI...The PR is a pretty good read.
“Our technology is the combination of three state-of-the-art technologies: the NanoVelcro CTC chip, laser capture microdissection and whole exome sequencing,” said Yi-Tsung Lu, MD, a postdoctoral scientist at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, and one of the article’s first authors. “This advancement will, in principle, allow us to track the genomic evolution of prostate cancer after we initiate a therapy and will allow us to better understand the mechanism of drug resistance that is common in prostate cancer patients. We hope the comprehensive understanding of cancer biology at the individual level will ultimately lead to better therapy choice for patients suffering from advanced cancer.”